Frexalimab (SAR441344) as a potential multiautoimmune disorder tackling mAB targeting the CD40-CD40L pathway undergoing clinical trials: a reviewTehreem Fatima, Aymar Akilimali, Riyan Imtiaz Karamat et al.|Annals of Medicine and Surgery|2024Cited by 7
“Is sotagliflozin a ‘wonder drug’? A review of its impact on cardiovascular, diabetic, renal, neuroprotective, and hepatic outcomes”Eeshal Fatima, Aymar Akilimali, Hamza Irfan et al.|Annals of Medicine and Surgery|2025Cited by 4
Epigenetic therapy for alcoholic hepatitis: can larsucosterol change the treatment landscape?Faiza Fatima, Aymar Akilimali, Mahnoor Fatima et al.|Annals of Medicine and Surgery|2025Cited by 0
Case Image: Mucinous Cystadenoma With Luteal Cell Proliferation During Early PregnancyAymar Akilimali, Ahila Ali, Saima Gulzar et al.|Clinical Case Reports|2025Cited by 0